Canada adds Vueway to macrocyclic MRI contrast options
The approval covers Vueway injection, a macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI in adults and children 2 years and older.
Bracco Imaging has received Health Canada approval for Vueway injection, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI. Health Canada approved the agent on April 10, according to the company.
The agent is indicated for adults and children 2 years and older to detect and visualize lesions with disruption of the blood-brain barrier or abnormal vascularity. The indication covers the central nervous system, including the brain, spine, and surrounding tissues, as well as body imaging.
The approved body indications include the head and neck, thorax, abdomen, pelvis, and musculoskeletal system, according to Bracco.
The recommended dose in Canada is 0.1 mL/kg body weight, equivalent to 0.05 mmol/kg, administered intravenously as a bolus. The product monograph states that safety and effectiveness have not been assessed in pediatric patients younger than 2 years.
Bracco said Vueway has the highest longitudinal relaxivity values among macrocyclic gadolinium-based contrast agents approved in major global markets. The company also said clinical studies showed effective contrast enhancement at half the 0.1 mmol/kg dose used with other GBCAs.
The Canada approval follows regulatory clearances in the U.S. in 2022 and the European Union in 2023. Bracco said the agent is now approved in 37 countries, with more than 4M patient doses administered worldwide.
Company:Bracco
Bracco coverage
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Niowave Lansing site to scale Ac-225 supply by 2028
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
30-year GE-UW tie expands into CT and theranostics research
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Recall issues and isotope shortages weigh on Radnostix Q1 revenue
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Ephemeral to build AI data platform for Plus CNS oncology programs
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm balloon-free EBUS scope targets pulmonary setup time
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST wins FDA clearance for Pro Diagnostic System
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M raise for breast imaging platform
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
UnitedHealthcare cites radiology costs in Maryland premium request
UnitedHealthcare is seeking an average 7.9% mid-year premium increase for some Maryland small-group plans. The insurer cited rising outpatient costs, including radiology, lab pathology, infusion, and radiation therapy.
Lumexa adds 4 imaging centers, including first UPMC JV site
Lumexa Imaging added 4 outpatient imaging centers across Pennsylvania, North Carolina, South Carolina, and Florida. The expansion includes acquired centers through joint ventures with UPMC and Advocate Health, plus 2 newly built locations.
PAI report finds 82% of U.S. physicians are now employed
A new PAI-Avalere report found that 82% of U.S. physicians are employed by hospitals, health systems, or corporate entities. Physician-owned settings now account for 18% of physicians and 36.1% of practices.